ADCT
ADC Therapeutics SA
Next earnings Aug 10, 2026 · consensus $-0.21 EPS, $19.8M rev
Last earnings -3.9% on 2026-05-04
$1.02
▼ -1.92%$1.02▼ -63.18%
over 1Y
L $0.98EODHDH $4.88
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-1.9%
1W-6.4%
1M-70.3%
3M-72.4%
YTD-71.0%
1Y-63.2%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Strong Buy
Revenue grew 14.9% YoY; but unprofitable (net margin -175.3%).
ADC Therapeutics SA shows $81.4M in FY2025 revenue (+14.9% YoY), a -175.3% net margin.
Financials · annual, by fiscal year
| Line item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | $210M | $69.6M | $70.8M | $81.4M |
| Gross profit | — | — | — | — |
| Operating income | -$123M | -$166M | -$131M | -$121M |
| Net income | -$157M | -$240M | -$158M | -$143M |
| Diluted EPS | -$2.01 | -$2.94 | -$1.62 | -$1.12 |
| Net margin | -74.9% | -345.1% | -222.8% | -175.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$129M
EV / EBITDA—
EV / Sales-1.6
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-110.1%
FCF yield-109.1%
Quality & risk
ROIC (est.)—
Free cash flow-$141M
Total debt$3.00M
Net cash$258M
Altman Z-Score-7.05 distress
Piotroski F-Score4/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+28.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-242026-06-24open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-06-012026-06-03open ↗8-KPeriod ending 2026-06-032026-06-03open ↗8-KPeriod ending 2026-06-012026-06-02open ↗10-QPeriod ending 2026-03-312026-05-04open ↗8-KPeriod ending 2026-05-042026-05-04open ↗
Frequently asked
- Is ADC Therapeutics SA (ADCT) a buy?
- ADCT currently carries a Avoid rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 14.9% YoY; but unprofitable (net margin -175.3%).
- What is ADC Therapeutics SA's quality score?
- ADCT scores 46.94117647058824/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001771910, latest 10-Q filed 2026-05-04) · EODHD · as of 6/26/2026, 6:07:10 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.